Hope Soars as New Vaccine Demonstrates Strong Immune Response to Combat Meningitis in Africa
Meningitis is a highly dangerous illness that can rapidly spread during an outbreak, posing a significant threat to individuals of all age groups, particularly those residing within the meningitis belt region.
Challenges in the availability and cost of quadrivalent meningococcal vaccines have restricted their usage within the “meningitis belt,” a region in sub-Saharan Africa that is particularly vulnerable to outbreaks of meningococcal and pneumococcal meningitis. Furthermore, the emergence of meningococcal strain X, which has the potential to cause epidemics throughout the “meningitis belt,” emphasizes the urgent need for a vaccine to safeguard against this specific strain.
A groundbreaking clinical trial has demonstrated the safety and effectiveness of a novel vaccine against meningococcal disease, a leading cause of meningitis and blood poisoning. The phase 3 trial assessed the immune response triggered by the new pentavalent vaccine NmCV-5 across five strains of meningococcal bacteria: A, C, W, Y, and X.
Conducted in Mali and The Gambia, the study involved 1,800 healthy individuals aged 2 to 29 years. The immune responses elicited by a single dose of NmCV-5 were compared with those generated by the licensed quadrivalent MenACWY-D vaccine. The findings revealed that NmCV-5 induced a robust immune response, surpassing the immune response triggered by MenACWY-D after 28 days across all age groups.
Excitingly, NmCV-5 also demonstrated a strong immune response against the emerging meningococcal X strain, for which there is currently no licensed vaccine available. The absence of safety concerns further supported the vaccine’s potential as an effective preventive measure.
The study, led by a team of researchers from the Medical Research Council (MRC) Unit The Gambia at the London School of Hygiene & Tropical Medicine (LSHTM) and researchers from Bamako in Mali, has been published in the prestigious New England Journal of Medicine.
The World Health Organization (WHO) estimates that meningitis caused 250,000 deaths in 2019 alone, underscoring the urgent need for affordable vaccines that can offer broad protection against various strains of meningococcal disease. Particularly in the ‘meningitis belt’ of sub-Saharan Africa, where supply and affordability issues have limited the use of quadrivalent meningococcal vaccines, the emergence of meningococcal X has raised concerns about potential epidemics.
Drawing inspiration from the success of the Meningitis Vaccine Project, which developed MenAfriVac, a highly effective meningococcal A vaccine, the Serum Institute of India and PATH collaborated to develop NmCV-5 with the goal of eradicating meningococcal disease in sub-Saharan Africa.
One of the key advantages of NmCV-5 lies in its more cost-effective production methods, which should enable the vaccine to be made available at a lower cost compared to existing quadrivalent vaccines.
This breakthrough addresses a major hurdle in ensuring widespread availability of the vaccine throughout the ‘meningitis belt.’ Importantly, the trial was specifically designed to provide the World Health Organization (WHO) with the necessary evidence to support the licensing of NmCV-5 for future epidemic control efforts.
“We are excited about the results of this study,” says co-author Dr. Ed Clarke.
“We expect NmCV-5 to provide children and young adults with reliable protection against meningitis caused by the meningococcal bacteria. The new vaccine will be a critical tool to interrupting and preventing devastating epidemics of meningitis in the meningitis belt. We hope it will ensure the goal of defeating epidemic meningitis by 2030, set out in the Global Roadmap, becomes a reality.”
Image Credit: BOUREIMA HAMA/AFP via Getty Images